AbSTrACT
The opportunistic pathogen non-typeable Haemophilus influenzae (NTHi) plays an important role in many chronic respiratory diseases including otitis media, chronic rhinosinusitis, cystic fibrosis and chronic obstructive pulmonary disease. Biofilm formation has been implicated in NTHi colonisation, persistence of infection and recalcitrance towards antimicrobials. There is therefore a pressing need for the development of novel treatment strategies that are effective against NTHi biofilm-associated diseases. SurgihoneyRO is a honey-based product that has been bioengineered to enable the slow release of H 2 O 2 , a reactive oxygen species to which H. influenzae is susceptible. Treatment of established NTHi biofilms with SurgihoneyRO significantly reduced biofilm viability through enhanced H 2 O 2 production and was shown to be more effective than the conventional antibiotic co-amoxiclav.
InTroduCTIon
Non-typeable Haemophilus influenzae (NTHi) is an opportunistic pathogen that plays an important role in a number of chronic diseases including otitis media, chronic rhinosinusitis, chronic obstructive pulmonary disorder and cystic fibrosis. The persistence of NTHi infections is often associated with biofilm formation, where individual bacterial cells form surface-associated aggregates surrounded by a self-produced extracellular polymeric substance. These heterogeneous bacterial populations play an important role in long-term NTHi colonisation of the human respiratory tract and are of significant clinical importance, responsible for causing infections after long periods of quiescence. 1 Bacteria residing within biofilms are protected from host immune responses, are less susceptible to antibiotic treatment and also have an increased propensity for development of antimicrobial resistance (AMR). Treatment of biofilm-associated infections is therefore challenging and with the increasing prevalence of AMR, there is a pressing need for the development of new treatment strategies. 2 A diverse range of factors can influence the growth and survival of bacteria within the human host. Understanding the interactions between the various members of the microbiota, their adaptive responses towards the unique environmental niches they occupy and the role of biofilms in colonisation can provide an avenue for the development of novel treatments. NTHi co-exists and competes with several other bacterial species in the human nasopharynx; however, its interaction with another opportunistic pathogen Streptococcus pneumoniae has attracted the most interest. Co-culture of S. pneumoniae with NTHi has been shown to stimulate upregulation of the pneumococcal virulence factor pyruvate oxidase (SpxB), an enzyme responsible for catalysing the production of hydrogen peroxide (H 2 O 2 ), 3 while increased expression of SpxB has also been demonstrated in monospecies pneumococcal biofilms. 4 5 The production of H 2 O 2 confers S. pneumoniae with a competitive advantage over other bacterial species occupying the nasopharynx 6 and has been shown to reduce H. influenzae viability in co-culture. 7 SurgihoneyRO is a licensed, CE-marked sterile honey that has been bioengineered to enable the controlled release of H 2 O 2 over a prolonged period. 8 This product has been shown to be effective in preventing biofilm formation and treating established biofilms formed by clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli. [9] [10] [11] Based on the susceptibility of NTHi towards exogenous H 2 O 2 , we hypothesised that this bioengineered product would be effective in the treatment of biofilms formed by this species.
MATerIAlS And MeThodS bacterial strains and growth conditions
Bacterial strains used in this study were isolated from nasopharyngeal swabs of children aged 4 years and under following written informed consent. NTHi was subcultured from frozen stocks onto Colombia agar with chocolated horse blood (Oxoid, UK) and incubated for 18 hours at 37°C and 5% CO 2 , following which colonies were resuspended in brain heart infusion (BHI) broth supplemented with 10 µg/mL Hemin and 2 µg/mL nicotinamide adenine dinucleotide (sBHI) and grown to mid-exponential phase for experiments. The P. aeruginosa reference strain PAO1-UW 12 and a clinical methicillin-resistant S. aureus (MRSA) isolate were subcultured onto Colombia blood agar plates (Oxoid) and grown in BHI.
Planktonic assays
Flat-bottomed 96-well plates (Fisher Scientific, UK) were inoculated with ~1.0×10 6 planktonic bacteria per well (grown in supplemented BHI). SurgihoneyRO and the non-engineered base honey (Acacia) were both prepared in sBHI and added to wells at final concentrations of 6 g/L to 319 g/L.
Acacia was sterilised using a 0.22 µm syringe filter. Supplemented BHI alone was added in place of treatments for untreated controls. Cultures were incubated at 37°C and 5% CO 2 for 18 hours then turbidity measured by absorbance (OD 595 ) using an EZRead 400 spectrophotometer (Biochrom; n=6).
biofilm assays
Mid-exponential planktonic cultures were used to inoculate individual wells of untreated six-well polystyrene plates (~1.0×10 8 planktonic bacteria per well; Corning Incorporated, USA). Cultures were incubated at 37°C and 5% CO 2 for 48 hours, replacing spent media with fresh sBHI (NTHi) or BHI (MRSA, P. aeruginosa) at 24 hours. Prior to treatment, spent media was removed and biofilms washed twice with Hanks' balanced salt solution (HBSS; Gibco, UK). Biofilms were treated with SurgihoneyRO or Acacia (both prepared in HBSS) at final concentrations of 7-213 g/L. To assess the effect of pH, biofilms were treated with HBSS adjusted to pH 6.3 (the pH of 71 g/L SurgihoneyRO in HBSS). For adjuvant assays, biofilms were treated with 300 µg/mL amoxicillin and 60 µg/mL clavulanic acid (co-amoxiclav). HBSS alone was added in place of treatments for untreated controls. Biofilms were incubated at 37°C and 5% CO 2 for 2 hour, following which the treatments were removed and biofilms washed twice with HBSS to remove unattached cells. Biofilms were resuspended in 1 mL HBSS by cell scraping, briefly vortexed, then serially diluted onto Colombia agar with chocolated horse blood (NTHi) or Columbia blood agar (MRSA, P. aeruginosa). Plates were incubated at 37°C and 5% CO 2 and colony forming units (cfu) enumerated (n=4).
Confocal microscopy
Mid-exponential planktonic cultures were used to inoculate 35 mm untreated glass-bottom CellView cell culture dishes (~1.0×10 8 planktonic bacteria per well; Greiner Bio One, UK). Cultures were incubated at 37°C and 5% CO 2 for 48 hours, replacing spent media with fresh sBHI at 24 hours. Media was removed, biofilms washed twice with HBSS, then treated with 71 g/L SurgihoneyRO, 300/60 µg/mL co-amoxiclav or HBSS alone (untreated control) for 2 hour at 37°C and 5% CO 2 . Treatments were removed and biofilms washed twice with HBSS before staining with a LIVE/DEAD Baclight Bacterial Viability Kit (Life Technologies, UK) as per manufacturer's instructions. Biofilms were examined using an inverted Leica SP8 confocal microscope using a 63× oil immersion lens with sequential scanning of 2 µm sections (Leica Microsystems, UK).
hydrogen peroxide measurements
SurgihoneyRO and Acacia were prepared at a range of concentrations between 7 and 213 g/L in HBSS and incubated at 37°C and 5% CO 2 for 2 hour. H 2 O 2 production was then measured using a Fluorimetric H 2 O 2 Assay Kit (Sigma-Aldrich, UK) as per manufacturer's instructions.
Statistical analyses
Statistical analyses were performed using one-way analysis of variance and Kruskal-Wallis multiple comparisons tests.
Comparative data with a P value of ≤0.05 were considered as statistically significant. 
Short report reSulTS

Surgihoneyro and the non-engineered base honey (Acacia) are equally efficacious against planktonic nThi
As H. influenzae has previously been shown to be sensitive towards H 2 O 2 produced by S. pneumoniae, we investigated whether SurgihoneyRO, on account of its bioengineered H 2 O 2 -generating properties, would be effective against planktonic NTHi. SurgihoneyRO treatment resulted in a dose-dependent response, with a significant reduction in growth at concentrations ≥178 g/L (P≤0.05) and a minimum inhibitory concentration (MIC) of 192 g/L (figure 1A). To determine if the bioengineering process increased the antibacterial properties of SurgihoneyRO, the response towards the non-engineered base honey (Acacia) was also investigated. Acacia demonstrated an antibacterial profile similar to that of SurgihoneyRO, also resulting in a significant reduction in growth at concentrations ≥178 g/L (P≤0.05) while possessing a marginally increased MIC of 255 g/L (figure 1A).
Surgihoneyro treatment reduces nThi biofilm viability through increased h 2 o 2 generation
Having established that both SurgihoneyRO and Acacia were both equally as effective in the treatment of planktonic NTHi, the response of the biofilm phenotype was then assessed. Treatment of established 48 hours in vitro biofilms with 71 and 142 g/L SurgihoneyRO for 2 hour resulted in a 4-log and 3-log reduction in viability, respectively (P≤0.05), while treatment with 213 g/L reduced viability 5-log (P≤0.01; figure 1B) . In comparison, treatment with the equivalent concentrations of Acacia had no effect on biofilm viability (P=0.75; figure 1B) . A dose-dependent increase in H 2 O 2 levels in the surrounding media was also observed when treating with both Acacia and SurgihoneyRO ( figure 1C) . SurgihoneyRO, however, produced significantly higher levels of H 2 O 2 at all concentrations tested, ranging from 10.7 to 71.2 µM in comparison with 0.24-6.5 µM generated when treating with the equivalent concentrations of Acacia. Furthermore, these data indicate that the minimum figure 1C) . To account for a pH-mediated response, NTHi biofilms were also treated with HBSS adjusted to pH 6.3 (the pH of 71 g/L SurgihoneyRO), revealing no effect on biofilm viability ( figure 1D ). To confirm that the response was H 2 O 2 mediated, biofilms were treated with 71 g/L SurgihoneyRO in the presence of 2 mg/mL catalase, revealing a reduction in SurgihoneyRO activity (figure 1E).
Surgihoneyro is more effective than co-amoxiclav in the treatment of nThi biofilms
The activity of SurgihoneyRO was compared with the conventional antibiotic co-amoxiclav and also whether it could improve antibiotic efficacy when used as an adjuvant. Treatment of established 48 hours in vitro biofilms with 71 g/L SurgihoneyRO for 2 hours resulted in a 5-log reduction in viability (P=0.029), whereas treatment with 300/60 µg/mL co-amoxiclav had no effect on viability (P=0.343; figure 2A ). Combined treatment did not improve co-amoxiclav efficacy (figure 2A). Confocal laser scanning microscopy confirmed the reduction in biofilm viability of 48 hours NTHi biofilms following treatment with 71 g/L SurgihoneyRO for 2 hours and also the ineffectiveness of co-amoxiclav ( figure 2C-E) . The confocal micrographs also demonstrated that SurgihoneyRO treatment had no obvious effect on overall biofilm biomass or ultrastructure, with all biofilms 70-80 µm in maximum height (figure 2B-E).
Surgihoneyro treatment is ineffective against in vitro MrSA and P. aeruginosa biofilms
The same treatment conditions successful in reducing NTHi biofilm viability (71 g/L SurgihoneyRO for 2 hour) were tested on established 48 hours in vitro biofilms formed by a clinical MRSA isolate and P. aeruginosa PAO1-UW to determine whether a similar reduction in viability would be observed (figure 3). Treatment of P. aeruginosa biofilms with either SurgihoneyRO or Acacia had no effect on viability (P=0.2539), whereas MRSA biofilms demonstrated a small but significant increase in viability when treating with both formulations (P=0.0286).
dISCuSSIon
NTHi biofilm-associated diseases manifesting in a number of chronic infective respiratory conditions including otitis media, chronic rhinosinusitis, cystic fibrosis, bronchitis, chronic obstructive pulmonary disease are inherently resistant to antimicrobials and thus represent a significant challenge in clinical settings. The susceptibility of H. influenzae to exogenous H 2 O 2 offers a potential avenue for the development of new treatment strategies. SurgihoneyRO, through its bioengineered H 2 O 2 -releasing properties, represents one such treatment. Interestingly, planktonic NTHi demonstrated similar susceptibility towards both SurgihoneyRO and the non-engineered base honey Acacia, indicating that the antibacterial properties of Acacia are sufficient against this phenotype in the absence of enhanced H 2 O 2 production. Acacia was, however, ineffective against established NTHi biofilms with viability remaining unaffected when treating with 213 g/L, evidencing the well-documented tolerance of the biofilm phenotype. In comparison, SurgihoneyRO reduced the viability of NTHi biofilms 4-log when treating with 71-142 g/L and 5-log when treating with 213 g/L, confirming that the bioengineering process enhanced the antibacterial efficacy, with 25.7 µM being the minimum effective concentration of H 2 O 2 . To overcome the recalcitrant nature of biofilms, it is becoming widely recognised that combination treatments targeting various aspects of the biofilm are required.
2 SurgihoneyRO was therefore tested as an adjuvant therapy with the conventional antibiotic co-amoxiclav. Whereas treatment with co-amoxiclav alone at a concentration 300 times in excess of the planktonic MIC (1 µg/ mL) had no effect on biofilm viability 71 g/L, SurgihoneyRO produced a 5-log reduction demonstrating its potential as an antibiotic-sparing therapy. When used in combination, there was no increase in antibiotic efficacy. This could be attributed to the fact that SurgihoneyRO had no impact on overall biofilm biomass, thus restricting antibiotic diffusion into the biofilm, or that the surviving cells were tolerant towards both treatments. Interestingly, treatment of P. aeruginosa and MRSA biofilms using the same conditions (71 g/L for 2 hour) was ineffective, having no effect on P. aeruginosa viability, and even increasing MRSA biofilm viability. This is in contrast to a previous study that demonstrated reduced seeding and disruption of biofilms formed by both species. 10 It is worth noting, however, that these biofilms were exposed to SurgihoneyRO for 24 hours as opposed to 2 hour in this study. While further validation of these data using biologically relevant models will be required, this study demonstrates a potential role for SurgihoneyRO as a novel adjuvant treatment in NTHi biofilm-associated infections. 
Take home messages
► SurgihoneyRO is effective in reducing non-typeable
Haemophilus influenzae biofilm viability. ► The antibacterial activity of SurgihoneyRO is associated with elevated hydrogen peroxide producing properties. ► SurgihoneyRO should be considered as an alternative to antibiotics for the treatment of NTHi biofilm-associated infections.
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